CRIS Current Research Information System

DALL'OLIO, FILIPPO GUSTAVO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.127
NA - Nord America 2.108
EU - Europa 1.664
AF - Africa 162
Continente sconosciuto - Info sul continente non disponibili 123
SA - Sud America 111
OC - Oceania 6
Totale 6.301
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.044
VN - Vietnam 696
IT - Italia 638
SG - Singapore 565
CN - Cina 438
DE - Germania 188
SE - Svezia 179
GB - Regno Unito 169
HK - Hong Kong 122
NL - Olanda 100
IN - India 91
BR - Brasile 86
FR - Francia 80
IE - Irlanda 56
RU - Federazione Russa 55
KR - Corea 48
BD - Bangladesh 46
CH - Svizzera 45
FI - Finlandia 45
TG - Togo 43
CA - Canada 32
ZA - Sudafrica 32
SC - Seychelles 29
CI - Costa d'Avorio 27
AT - Austria 22
JP - Giappone 22
JO - Giordania 21
BG - Bulgaria 17
NG - Nigeria 16
UA - Ucraina 13
ES - Italia 12
MX - Messico 12
PL - Polonia 12
TH - Thailandia 11
BE - Belgio 10
EE - Estonia 9
IQ - Iraq 9
PH - Filippine 9
TR - Turchia 9
ID - Indonesia 8
PK - Pakistan 8
AR - Argentina 7
EC - Ecuador 7
EG - Egitto 7
NI - Nicaragua 6
TW - Taiwan 6
CO - Colombia 5
AU - Australia 4
CR - Costa Rica 4
OM - Oman 3
PY - Paraguay 3
RO - Romania 3
AE - Emirati Arabi Uniti 2
HN - Honduras 2
HR - Croazia 2
IR - Iran 2
PE - Perù 2
PS - Palestinian Territory 2
PT - Portogallo 2
SA - Arabia Saudita 2
SV - El Salvador 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AL - Albania 1
AO - Angola 1
CL - Cile 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KI - Kiribati 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MN - Mongolia 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SO - Somalia 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
Totale 6.178
Salva come PNG Salva come JPEG
Città #
Singapore 405
Ashburn 249
Chandler 184
San Jose 144
Dong Ket 140
Fairfield 138
Southend 135
Ho Chi Minh City 121
Hanoi 117
Hong Kong 109
Santa Clara 104
Hefei 99
Bologna 98
Seattle 76
Woodbridge 67
Beijing 66
Houston 66
Rome 61
Wilmington 57
Dublin 56
Dallas 55
Princeton 51
Council Bluffs 50
Milan 49
Boardman 44
Lomé 43
Los Angeles 43
Cambridge 41
New York 41
Seoul 38
Bern 35
Helsinki 35
Lauterbourg 34
Abidjan 27
Turin 24
Amman 21
Ann Arbor 19
Buffalo 19
Da Nang 19
Frankfurt am Main 19
Munich 18
Berlin 17
Abeokuta 16
Bremen 16
Florence 16
Sofia 16
São Paulo 16
Tokyo 16
Haiphong 15
Johannesburg 15
Westminster 15
Redondo Beach 14
Vienna 14
Montreal 13
San Diego 13
Des Moines 12
Redmond 12
Nanjing 11
Nuremberg 11
Ravenna 11
Can Tho 10
Bengaluru 9
Jinan 9
Brussels 8
Chicago 8
Guangzhou 8
Orem 8
Turku 8
Falkenstein 7
Manchester 7
Modena 7
Moncalieri 7
Phoenix 7
Shenyang 7
Stockholm 7
Warsaw 7
Amsterdam 6
Biên Hòa 6
Bắc Giang 6
Changsha 6
Hải Dương 6
London 6
Managua 6
Mexico City 6
Redwood City 6
Rio de Janeiro 6
Torino 6
Visakhapatnam 6
Bari 5
Boston 5
Brescia 5
Brooklyn 5
Bühl 5
Olalla 5
Padova 5
Paris 5
Phủ Lý 5
Pune 5
Quận Bình Thạnh 5
Salt Lake City 5
Totale 3.742
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 470
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 294
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC 291
The 'surprise' question in advanced cancer patients: A prospective study among general practitioners. 279
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 277
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 274
Adjuvant chemotherapy for resected colorectal cancer metastases: literature revision and meta-analysis 262
CLINICOPATHOLOGICAL, MOLECULAR AND ONCOLOGICAL FEATURES OF SPORADIC EARLY ONSET COLORECTAL CANCERS 257
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data 255
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 211
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 210
Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding 206
Clinical significance of ROS1 5’ deletions in non-small cell lung cancer 183
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter 181
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors 162
Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role? 161
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study 159
Clinical and demographic factors associated to the place of death in advanced cancer patients assisted at home in Italy 156
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 150
Expected and non-expected immune-related adverse events detectable by CT 150
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 148
Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non–Small Cell Lung Adenocarcinoma 144
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough 142
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 139
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. 137
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 133
Pneumatosis intestinalis and spontaneous perforation associated with drug toxicity in oncologic patients: A case series 132
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 126
Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect 121
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 120
Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates 103
Role of PD-L1 assessment in advanced NSCLC: does it still matter? 84
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 69
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50% 62
Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors 53
Totale 6.301
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.007
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.007
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022546 0 13 24 33 54 18 21 57 38 44 164 80
2022/2023839 60 148 53 99 65 63 26 53 127 18 57 70
2023/2024289 35 35 15 30 21 51 4 26 14 13 21 24
2024/20251.002 70 113 73 54 127 42 54 69 42 108 73 177
2025/20262.414 257 272 177 146 224 137 186 99 503 216 87 110
2026/2027133 67 66 0 0 0 0 0 0 0 0 0 0
Totale 6.301